key: cord-0837130-wwfllrxg
authors: Boddu, Sirisha Kusuma; Aurangabadkar, Geeta; Kuchay, Mohammad Shafi
title: New onset diabetes, type 1 diabetes and COVID-19
date: 2020-11-17
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2020.11.012
sha: 7d5cdb723b56975dac9bc3353c27752c7a37e1db
doc_id: 837130
cord_uid: wwfllrxg

BACKGROUND AND AIMS: New data has emerged regarding higher risk of coronavirus disease 2019 (COVID-19), and its severity and complications in patients with type 2 diabetes mellitus (T2DM). However, there is a dearth of evidence regarding type 1 diabetes mellitus (T1DM). This article explores the possibility of COVID 19 induced diabetes and highlights a potential bidirectional link between COVID 19 and T1DM. METHODS: A literature search was performed with Medline (PubMed), Scopus, and Google Scholar electronic databases till October 2020, using relevant keywords (COVID-19 induced diabetes; COVID-19 and type 1 diabetes; COVID-19 induced DKA; new-onset diabetes after SARS-CoV-2 infection) to extract relevant studies describing relationship between COVID-19 and T1DM. RESULTS: Past lessons and new data teach us that severe acute respiratory syndrome coronaviruses (SARS CoV-1, -2) can enter islet cells via angiotensin converting enzyme-2 (ACE-2) receptors and cause reversible β-cell damage and transient hyperglycemia. There have been postulations regarding the potential new-onset T1DM triggered by COVID-19. This article reviewed all the available evidence regarding the impact and interlink between COVID-19 and Τ1DM. We also intended to explore the mechanisms behind the viral etiology of Τ1DM. CONCLUSIONS: SARS CoV-2 induces new-onset diabetes with diabetic ketoacidosis at presentation in several individuals. However, at present, there is no hard evidence that SARS CoV-2 induces T1DM. Long term follow-up of children and adults presenting with new-onset diabetes during this pandemic is required to fully understand the type of diabetes induced by COVID-19.

Since the onset of COVID 19 pandemic, a great deal of evidence has emerged regarding its relationship with T2DM. However, reports on effects of SARS-CoV-2 infection on people with T1DM have been more recent and relatively sparse. T1DM

constitutes about 5% of all diagnosed cases of diabetes and its global incidence is increasing at an alarming rate of about 3% every year (1) . Pre-existing diabetes mellitus is purported to be one of the high-risk factors for developing COVID-19 and related complications (2) . Indeed, there have been reports of Covid-19 induced severe metabolic decompensation of pre-existing or new-onset diabetes such as diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) (3) (4) (5) (6) (7) .

More characteristically, SARS-CoV-2 has been suggested as a potential inducer of new-onset T1DM (8) . Although coronavirus mediated islet cell damage does not seem to be a novel phenomenon, as evidenced by the experience from previous coronavirus (SARS and MERS) epidemics (9) ; we specifically wanted to explore the underlying mechanisms of hyperglycemia particularly in relation to COVID 19. In this review, we also examine the morbidities and mortality of covid-19 in people with T1DM.

T1DM is a genetic autoimmune condition where β-cells are destroyed by the autoreactive CD4+ and CD8+ T cells. Although >50 candidate genes were identified, poor concordance of T1DM (<50%) in monozygotic twins suggests players beyond genetics. Regional differences in prevalence with incidence in migrants conforming to the incidence of the region of destination, and the North-South gradient with J o u r n a l P r e -p r o o f higher figures in northern latitudes indicate non-genetic environmental influences.

Well established seasonality of new-onset T1DM led to exploration of viral etiology (10) . The relationship between viral infections and T1DM is complex. Mouse models have demonstrated that while certain viruses could be detrimental to the β-cells and initiate autoimmunity, others can be protective and have preventive effects.

However, one needs to exercise caution when extrapolating these findings to human subjects (11).

Conceptually, virus induced β-cell damage is due to either 1) direct lytic effects of viral replication and/or, 2) host inflammatory response mediated damage by autoreactive CD+T cells, leading to autoimmunity (Figure 1 ). While destruction of >90% of β-cells by direct viral mediated damage leads to non-autoimmune diabetes, limited lysis releases islet cell antigens, which in conjunction with enhanced immune response paves way for autoimmunity. Evidence for the earlier instance is most notable from the cases of fulminant T1DM, reported almost exclusively from Japan and predominantly in adults, preceded by minor upper respiratory or gastrointestinal infections, Mumps, HHV6, Coxsackie B3, B4, HSV, Hepatitis A, Influenza B and parainfluenza. Described as type 1B diabetes, fulminant T1DM is characterized by acute onset of hyperglycemic ketoacidosis, very short (1 week) duration of diabetes symptoms (polyuria, thirst, and body weight loss), absence of islet-related autoantibodies, extremely low C-peptide levels, elevated serum pancreatic enzyme levels, and a HbA1c less than 8.5% on the first visit (12) (13) (14) (15) (16) (17) .

Nevertheless, it is the limited β-cell destruction with release of sequestered islet cell antigens and activation of autoreactive T-cells that result in long-term autoimmune damage and subsequent T1DM. In children with recently diagnosed diabetes, J o u r n a l P r e -p r o o f hyperexpression of major histocompatibility complex -1 (MHC-1) and interferon-α was observed within the islets that are otherwise completely devoid of these markers (18) . These markers characteristically increase antigen mediated activation of CD8+T Cells, and it is most likely that their enhanced production is viral mediated.

The pathological processes mediating chronic β-cell damage are varied. The foremost contender is molecular mimicry, where viral epitope shares a resemblance with host islet protein causing cross-reactivity and autoimmune T cell response against host tissue in susceptible individuals. However, studies aiming to demonstrate molecular mimicry are inconclusive. It is likely that molecular mimicry can accelerate the autoimmune process once it is already started, rather than initiate it on its own (18) . Other proposed mechanisms are bystander T-cell activation, the activation of a T cell independent of an antigen specific T-cell receptor stimulation, and bystander damage, where destruction of β-cells is accelerated by the proinflammatory cytokines released due to infection of adjacent pancreatic cells like alpha, exocrine, endothelial and neuronal cells (19) (20) (21) . In addition to the decreased insulin release due to β-cell loss, proinflammatory mediators can result in functional defects like defective glucose mediated insulin release and delay in the conversion of proinsulin to insulin.

Another crucial element is the seeming inability of β-cells to clear viral infections, when compared with alpha cells. Chronicity of β-cell infection was apparent from postmortem studies where expression of viral capsid protein VP1 was detected in the islets of >60% T1DM organ donors while only 8% of non-T1DM samples showed its presence (21) . Chronic β-cell infection results in persistent overexpression of J o u r n a l P r e -p r o o f MHC-1 leading to continuous presentation of beta cell epitopes to the immune system, facilitating autoimmunity.

Though many viruses came to be associated with T1DΜ, namely, enteroviruses (especially Coxsackie B1, B4), mumps, rubella and CMV; so far the most robust evidence for viral induced T1DM is seen with enterovirus, an ssRNA virus of picornavirus family, when enteroviral RNA was detected in the blood of recently diagnosed patients with T1DM (Table 1) . A systematic review and meta-analysis showed a significant association between enterovirus infection and T1DM-related autoimmunity (OR: 3.7, 95%CI: 2.1-6.8) and clinical T1DM (OR: 9.8, 95%CI: 5.5-17.4) (33) . The Epidemiological Determinants of Diabetes in Young (TEDDY) study that followed 8676 newborn babies with increased genetic risk for T1DM, conferred by a specific HLA genotype, over 15 years, observed that number of respiratory infections occurring in a 9-month period was associated with the subsequent risk of autoimmunity (p < 0.001). For each 1/year increase in infections, the hazard of islet autoimmunity increased by 5.6%. Autoantibodies were more commonly detected in patients with severe respiratory disease, and interestingly, coronaviruses were identified among the different pathogens involved (34) . In the latest update of the TEDDY study, persistent presence of enterovirus B species in a child's stool appears to predict development of islet autoimmunity, especially antibodies against Insulin

Nonetheless, there is substantial epidemiological data contradicting the viral origins of β-cell autoimmunity. Viral data from non-obese diabetic (NOD) mice has shown that coxsackie B3 (CB3) and lymphocytic choriomeningitic virus (LCMV) can offer protection from T1DM by promoting immune tolerance. Early exposure to infections J o u r n a l P r e -p r o o f was also deemed to educate the immune system leading to reduced incidence of autoimmune diseases like T1DM as seen in countries with low SES where the incidence of infections is high (33).

Angiotensin converting enzyme (ACE) is the key enzyme in mediating the effects of renin angiotensin aldosterone system (RAAS) by converting angiotensin-I to II. The more recently identified ACE2, a novel homolog of ACE that degrades angiotensin-II to angiotensin-I-VII, was found to be the functional receptor for SARS CoV-1 and -2 (36) . ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS-CoV-1, and -2 (37) . Study of 72 human tissues confirmed ACE2 mRNA expression in tissues other than the lung and gastrointestinal system, like testis, cardiovascular, renal, and pancreas (38, 39) . Studies from 2003 SARS-CoV-1 epidemic evidenced that even milder SARS pneumonitis cases who did not receive glucocorticoid medications, had higher fasting blood glucose; and hyperglycemia in turnwas an independent predictor of higher mortality and morbidity (40) . A follow up study in 2010 of the same cohort, investigating pathogenesis of pancreatic lesions, also found that pancreatic islets are strongly immune-positive for ACE2 while exocrine tissues are only weakly positive.

Insulin dependent diabetes occurred during the hospitalization in 20 of the 39 patients (age: 47.2±2.2 years) who received no corticosteroids during the course of SARS disease. Out of these, six had diabetes at discharge. But after 3 years of follow-up, only two had persistent diabetes, suggesting that the damage incurred by islet cells is acute and mostly transient (9).

J o u r n a l P r e -p r o o f Earlier reports from Italy and China noticed a curious lack of people with T1DM in hospitalized cohorts of SARS-CoV-2, that made authors wonder if the immunological attributes of T1DM are in some way protective (41, 42) . However, it is more plausible that lock-down measures with special directives of caution to people with pre-existing conditions like diabetes, fear of infection, more parental supervision while staying at home encouraged young people to avoid crowded places as well as take better care of their diabetes. Nonetheless, as we try to comprehend this unfolding pandemic, new evidence is emerging that Covid-19 not only increases the risk of DKA and mortality in those with T1DM & T2DM, but also could potentially induce new-onset T1DM.

Diabetes has long been associated with increased susceptibility to and severity of infections. Hyperglycemia, by altering immune response and causing cytokine dysregulation, is an inherently proinflammatory and procoagulant state (43) (44) (45) (46) (47) . In an observational study on 59 hospitalized adult Covid-19 patients, patients with hyperglycemia had higher IL-6 and D-dimer levels, which reduced significantly with optimal glucose control, supporting the permissive role hyperglycemia plays in enhancing inflammation and creating procoagulant state independent of viral mediation (4). Hence T1DM and T2DM, especially with poor glycemic control become high-risk pre-existing conditions for many bacterial and viral infections including SARS-CoV-2.

Multiple centers reported that Covid-19 induces DKA and increases the length of hospital stay in those with diabetes (5) . Even as evidence mounts on the increased Covid-19 related mortality and morbidity in those with pre-existing diabetes, most of these observations were in relation to people with T2DM, who typically have a range J o u r n a l P r e -p r o o f of co-morbidities like hypertension, obesity, cardiovascular disease etc., unlike the relatively younger and otherwise fit T1DM community (6, 48) .

In a preliminary report from a multicenter USA study, out of 64 adults with T1DM who have confirmed or suspected COVID-19, more than 50% reported hyperglycemia, and nearly one-third had DKA (49) . In a nationwide analysis in England, adjusted for age, sex, deprivation, ethnicity, and geographical region, compared with people without diabetes, the odds ratios for in-hospital COVID-19-related death were 3·51 (95% CI 3·16-3·90) in people with T1DM and 2·03 (1·97-2·09) in people with T2DM.

These effects were attenuated to ORs of 2·86 for T1DM and 1·80 for T2DM when also adjusted for underlying cardio/cerebrovascular disease, though other potential confounders like BMI, hypertension, kidney disease, and tobacco smoking were not adjusted for (50) . Moreover, people younger than 40 years with either type of diabetes were at very low absolute risk of in-hospital death with COVID-19, further indicating that comorbidities might have contributed significantly to the increased mortality. Moreover, evidence hitherto points towards a milder covid-19 in children with better prognosis when compared with adults (51).

In a population-based cohort study of all the people with T1DM and T2DM who were registered to general practice in England, Covid-19 related mortality is higher (Hazard ratio 2.23 in T1DM, 1.61 in T2DM) in those with prior higher HbA1c of 10% (86 mmol/mol) versus in those with a HbA1c of 6.5-7.0% (48-53 mmol/mol). In addition, older age (>70 years), non-white ethnicity, co-morbidities like previous stroke or cardiac failure or renal compromise and socio-economic deprivation is associated with increased mortality, in both T1DM and T2DM (52) .

These studies indicate that Covid-19 increases mortality even in people with T1DM, especially in older age groups with co-existing renal or cardiac disease. In patients J o u r n a l P r e -p r o o f with diabetes, it is important to maintain optimal glycemic control by frequent blood glucose and ketone measurements, and adjusting insulin regime accordingly.

As it is becoming more evident that the length of hospital-stay, risk of complications and overall mortality from COVID-19 are higher with poor glycemic control, this could be partly due to the adverse effects of certain therapies currently under trials to treat severe covid-19 (52, 53) .

Hydroxychloroquine, an immunomodulatory that was extensively used during the initial phases of the pandemic, can decrease insulin degradation at the cellular level and stimulate insulin-mediated glucose transport, resulting in potential hypoglycemia (54, 55) . On the other hand, antiviral drugs such as lopinavir and ritonavir could lead to hyperglycemia and worsen glycemic control (56) . Glucocorticoids, which were seen to improve outcomes in COVID-19 related severe acute respiratory distress syndrome and hence became an integral part of treatment regime for hospitalized patients, can lead to marked hyperglycemia by reducing insulin sensitivity as well as by interfering with the actions of glucagon like peptide-1 and stimulating production of glucagon (57) . Some of the challenges in managing individuals with T1DM during COVID-19 pandemic are given in table 2.

demonstrate that SARS-CoV-2 uses the same ACE2 receptor as SARS-CoV-1 for host cell entry (58, 59) . As the substantially high transmissibility of SARS-CoV-2 relative to SARS-CoV-1 is becoming evident, one may speculate that the new virus J o u r n a l P r e -p r o o f might exploit cellular attachment factors with higher efficiency than SARS-CoV-1, causing more robust infection of ACE2+ cells. (66) . Though none of these reports prove causality, the role of direct viral cytopathic damage of pancreas can not be discounted, and it seems that endocrine islet cells are particularly more vulnerable to the viral insult.

New-onset hyperglycemia is being increasingly described with Covid-19 in adults without a previous history of diabetes, albeit with significant mortality and morbidity.

resistance could lead to stress hyperglycemia, it is uncertain as to what extent the direct viral destruction of islet cells with decreased insulin production and release might be contributing (67) (Figure 2) . Covid-19 can also act as an infectious trigger SARS-CoV-2 reduces ACE2 expression, leading to decreased degradation of angiotensin II, which can cause increased secretion of aldosterone and renal potassium loss. Whether this phenomenon was the basis for severe hypokalemia seen in the PCR positive child, needs further evidence. There are a few case reports of COVID-19 inducing acute onset diabetes and DKA in several individuals, mimicking T1DM. However, on follow-up there was reduced need for insulin and ultimately insulin could be discontinued in all the three patients. At last follow-up, these patients had controlled glycemia on oral antihyperglycemic medication (7, 72) .

At this point, it would be mostly conjectural to say that SARS-CoV-2 exposure 

DIAMOND Project Group Incidence and trends of childhood type 1 diabetes worldwide 1990-1999

Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv

Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care

COVID-19 infection may cause ketosis and ketoacidosis

COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The lancet

Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature

New-Onset Type 1 Diabetes in Children During COVID

Multicenter Regional Findings in the U.K. Diabetes Care

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Viral trigger for type 1 diabetes: pros and cons

Virus infections in type 1 diabetes. Cold Spring Harb Perspect Med

A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group

Fulminant type 1 diabetes: a nationwide survey in Japan

A case of fulminant type 1 diabetes mellitus after influenza B infection

A case of fulminant type 1 diabetes associated with significant elevation of mumps titers

A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody

Fulminant Type 1 diabetes mellitus associated with acute hepatitis A

A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes

Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry

Viral infections in type 1 diabetes mellitus--why the β cells?

Detection of enterovirus RNA in peripheral blood mononuclear cells of type 1 diabetic patients infection

Coxsackievirus B1 is associated with induction of β-cell autoimmunity that portends type 1 diabetes

VirDiab Study Group. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes

Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY)

Isolation of enterovirus strains from children with preclinical Type 1 diabetes

Increased prevalence of enteroviral RNA in blood spots from newborn children who later developed type 1 diabetes: a population-based casecontrol study

Enterovirus infections as a risk factor for type I diabetes: virus analyses in a dietary intervention trial

Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase

Evidence for molecular 549 mimicry between human T cell epitopes in rotavirus and pancreatic islet 550 autoantigens

Immunoproteomic Profiling of Antiviral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays

Serological evaluation of possible exposure to Ljungan virus and related parechovirus in autoimmune

Longitudinal study 533 of parechovirus infection in infancy and risk of repeated positivity for multiple islet 534 autoantibodies: the MIDIA study

Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies

Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: the TEDDY study

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 is expressed in human pancreatic islet β-cells and is upregulated by inflammatory stress. bioRxiv

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Lack of type 1 diabetes involvement in SARS-COV-2 population: Only a particular coincidence

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Infections in patients with diabetes mellitus

Sepsis in diabetes: A bad duo

Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study

Excess Risk of Dying From Infectious Causes in Those With Type 1 and Type 2 Diabetes

Fasting plasma glucose is an independent predictor for severity of H1N1 pneumonia

Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study

Type 1 Diabetes and COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the U.S. Diabetes Care

Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The lancet

Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized J o u r n a l P r e -p r o o f in the United States

Hypoglycemia due to hydroxychloroquine, an uncommon association but to keep in mind, case report and review of literature

Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis

Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings

Corticosteroids in diabetes patients infected with COVID-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Clinical features of COVID-19-related liver functional abnormality

Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members

Acute pancreatitis in a COVID-19 patient

COVID19 induced acute pancreatitis and pancreatic necrosis in a patient with type 2 diabetes

Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia

Emerging phenotype of SARS-CoV2 associated pancreatitis

Why is hyperglycemia worsening COVID-19 and its prognosis?

Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children? Diabetes Care

Paediatric critical care referrals of children with diabetic ketoacidosis during the COVID-19 pandemic

Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19

COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes

Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19

New-Onset Diabetes in Covid-19